Introduction
Something remarkable happened in March 2026. The American College of Cardiology and the American Heart Association released their updated dyslipidemia guidelines—and for the first time in history, they recommended that every adult should have their lipoprotein(a) measured at least once in their lifetime .
This is a Class I recommendation. In medical language, that means it is a definitive, evidence-based standard of care. It is not a suggestion. It is not experimental. It is what doctors are now expected to do .
If you have been reading my work for any length of time, you know why this matters. For years, I have been writing about Lp(a)—what it is, why it matters, and why conventional medicine has largely ignored it. I wrote two books on the subject. I reversed my own heart disease by addressing Lp(a) at its root cause.
The world is finally catching up.
But here is the problem: most patients do not know what Lp(a) is. They do not know what ApoB is. They do not know what a CAC score means. When their doctor orders these tests, they may feel confused or frightened.
This article will prepare you. By the time you finish reading, you will understand what these new tests measure, why the guidelines changed, and—most importantly—what to do if your results come back high.
What the 2026 Guidelines Actually Say
The new guidelines introduce several major changes. Here are the three that matter most to you :
- Universal Lp(a) Testing
Every adult should have their Lp(a) measured at least once. This is a lifetime test because your Lp(a) level is largely determined by genetics and remains relatively stable. The threshold for elevated risk is 125 nmol/L (approximately 50 mg/dL). Above this level, cardiovascular risk increases substantially. At levels of 250 nmol/L or higher, the risk of heart attack or stroke at least doubles . - Selective ApoB Testing
Apolipoprotein B (ApoB) is now recommended for people with diabetes, high triglycerides, metabolic syndrome, or those who have reached their LDL goals but still seem to be at risk. ApoB measures the actual number of atherogenic particles in your blood—not just the cholesterol they carry. It is a more precise marker than LDL alone . - Expanded Use of Coronary Artery Calcium (CAC) Scoring
CAC scoring is a non-invasive scan that detects calcified plaque in your coronary arteries. Under the new guidelines, any nonzero CAC score signals subclinical atherosclerosis and triggers treatment goals. A score above 300 approaches secondary prevention risk levels. A score above 1,000 warrants very high-risk management .
These three tests—Lp(a), ApoB, and CAC—give your doctor a far more complete picture of your true cardiovascular risk than the standard cholesterol panel ever could.
Why the Guidelines Changed Now
The shift was long overdue. Here is what the evidence showed:
LDL alone is not enough. The old approach focused almost exclusively on LDL cholesterol. But studies consistently showed that people with “normal” LDL were still having heart attacks. Something else was causing the damage. That something, in large part, is Lp(a) .
Lp(a) is common. Approximately one in five people worldwide has elevated Lp(a). Yet fewer than 1% have ever been tested. The guidelines committee recognized this as a massive blind spot in cardiovascular prevention .
Lp(a) is causal. Unlike many risk markers that are merely associated with disease, Lp(a) has been shown to be causally linked to atherosclerosis and aortic valve disease. Genetic studies confirm that higher Lp(a) directly causes more cardiovascular events .
Early detection enables early action. Because Lp(a) levels are genetic and stable, a single test in early adulthood can identify a lifetime of elevated risk. This allows for aggressive management of modifiable risk factors decades before a heart attack occurs.
The guidelines committee concluded that the evidence was too strong to ignore. The era of Lp(a) testing has begun.
What Your Doctor Will Likely Tell You
When your Lp(a) comes back high, your doctor will likely say something like this:
“Your Lp(a) is elevated. This is genetically determined, so lifestyle changes won’t lower it. There is no approved drug specifically for Lp(a). We will focus on aggressively lowering your LDL and managing your other risk factors.”
This is accurate, as far as it goes. The guidelines do state that lifestyle changes minimally affect Lp(a) levels and that no therapies are currently approved solely for Lp(a) lowering .
But it is also incomplete. And this is where my book, Reverse Heart Disease: No Lifelong Suffering, provides the missing piece.
What the Guidelines Miss: The Root-Cause Perspective
The guidelines identify Lp(a) as a risk factor. They tell you to manage it by intensifying other treatments. But they do not answer the most important question: Why is your body producing so much Lp(a) in the first place?
Lp(a) is not a random genetic error. It is a repair particle. Your liver produces it to patch cracks in weak artery walls. Those cracks develop when the collagen structure of your arteries is compromised—most commonly due to long-term vitamin C deficiency.
A 1990 US patent proved that the primary component of arterial plaque is Lp(a), not ordinary LDL cholesterol. The body is not trying to harm you. It is trying to repair structural damage using the only materials it has available.
If you focus only on lowering Lp(a) with drugs, you are treating the number while ignoring the reason it is elevated. If you focus on strengthening the artery wall—by providing the nutrients collagen needs to form properly—you address the root cause. The need for Lp(a) patches diminishes naturally.
This is the argument I make in my book. It is not a rejection of the new guidelines. It is a completion of them.
How to Prepare for the Conversation With Your Doctor
If your doctor orders these tests—or if you request them yourself—here is how to approach the results.
Step 1: Get the tests.
Ask for Lp(a), ApoB, and a CAC scan if you are over 40 and have risk factors. These are now guideline-supported. Your doctor should not refuse.
Step 2: Understand your numbers.
- Lp(a) below 125 nmol/L: lower risk.
- Lp(a) 125–250 nmol/L: moderately elevated risk.
- Lp(a) above 250 nmol/L: significantly elevated risk.
- ApoB: targets vary by risk level, but lower is better.
- CAC score of zero: no detectable calcified plaque. This is reassuring but does not rule out soft plaque.
- CAC score above zero: atherosclerosis is present. Treatment is indicated.
Step 3: Listen to your doctor’s recommendations.
The guidelines recommend intensified LDL lowering and aggressive risk factor management. Statins, ezetimibe, and PCSK9 inhibitors may be discussed. These have a role.
Step 4: Add the root-cause perspective.
While following your doctor’s advice, understand that managing numbers is not the same as repairing arteries. Ask yourself: Am I providing my body with the nutrients it needs to build strong collagen? Am I getting enough vitamin C, lysine, and proline? Am I addressing the reason my artery wall was weak in the first place?
Step 5: Read the full explanation.
My book Reverse Heart Disease: No Lifelong Suffering explains the complete science behind Lp(a)—why it rises, how it causes plaque, and what you can do about it at the root-cause level. It is the guide that the guidelines themselves do not provide.
What This Means for You
The 2026 guidelines are a victory for truth. They acknowledge what many of us have been saying for years: Lp(a) matters. ApoB matters. The standard cholesterol panel is not enough.
But a guideline can only go so far. It can tell you to test. It cannot tell you why your body produces the very particles that cause disease. That understanding requires going deeper—to the cellular level, to the nutrients your arteries are made of, to the root cause.
You now have a choice. You can follow the guidelines and manage your numbers. Or you can go further and address why those numbers are abnormal in the first place.
The first path manages risk. The second path pursues health.
My book exists for those who choose the second path.
Dr. Balaram Dhotre is a PhD medicinal chemist, cellular nutritionist, and the author of Unraveling the Root Cause of Chronic Diseases and Reverse Heart Disease: No Lifelong Suffering. He writes at lyproc.com to help people understand the true root cause of chronic illness and reclaim their health.
[Click here to get your copy of Reverse Heart Disease: No Lifelong Suffering on Amazon]
My Books
Links on Amazon
Unraveling The Root Cause of Chronic Diseases:
Reverse Heart Disease: No Lifelong Suffering
——————————————————————————————————————-